Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    22

Stocks News & Analysis

stocks

Lower fair value on ASX best idea

Shares are still undervalued despite drop in profit margins.
stocks

We raise our near-term gold price assumptions

Our coverage remains overvalued.
stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,161.5050.00-0.54%
CAC 408,330.9716.23-0.19%
DAX 4025,286.24134.42-0.53%
Dow JONES (US)49,149.6342.36-0.09%
FTSE 10010,184.3547.000.46%
HKSE26,882.22117.59-0.44%
NASDAQ23,471.75238.13-1.00%
Nikkei 22553,785.25555.98-1.02%
NZX 50 Index13,659.5298.19-0.71%
S&P 5006,926.6037.14-0.53%
S&P/ASX 2008,837.3043.70-0.49%
SSE Composite Index4,101.5224.57-0.60%

Market Movers